Sponsor:
Stanford University
Code:
NCT06868381
Conditions
Cardiac Sarcoidosis
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Baricitinib (LY3009104) 4 mg
Brief summary:
Conditions
Cardiac Sarcoidosis
Study ID
NCT06868381
Start date
Apr 1, 2026
Status verified date
Nov, 2026
Completion date
Dec 1, 2028
Anticipated
Primary completion date
Jul 1, 2028
Anticipated
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Enrollment
10 participants
Anticipated
Intervention Model
Single group
Primary purpose
Treatment
Arms
experimental: baricitinib + steroid-sparing drug +/- glucocorticoid taper
Interventions
Baricitinib (LY3009104) 4 mg
Primary outcome measure
Central contacts
Travis Deal
tdeal1@stanford.eduLocations
Stanford University
Recruiting
Palo Alto, California, United States, 94304-2210
Contacts
Principal Investigator:
Matthew C Baker, MD, MS
Sponsor
Stanford University
Last update posted
Nov 19, 2026
Last verified
Nov, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-20. This information was provided to ClinicalTrials.gov by Stanford University on 2026-11-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.